Gerald D Hurst

US Patent:

RE38416, Feb 3, 2004

Filed:

Oct 19, 2000

Appl. No.:

09/693213

Inventors:

Charles R. Petrie - Woodinville WA
Rich B. Meyer - Redwood CA
John C. Tabone - Bothell WA
Gerald D. Hurst - Iowa City IA

Assignee:

Epoch Biosciences, Inc. - Bothell WA

International Classification:

C07H 1904

US Classification:

536 261, 536 267, 536 268, 536 2612, 536 2613, 536 2614, 536 276, 536 278, 536 2781, 536 285, 536 2854, 536 245

Abstract:

This invention is directed to novel substituted nucleotide bases with a crosslinking arm which accomplish crosslinking between specific sites on adjoining strands of oligonucleotides a oligodeoxynucleotides. The invention is also directed to oligonucleotides comprising at least one of these crosslinking agents and to the use of the resulting novel oligonucleotides for diagnostic and therapeutic purposes. The crosslinking agents of the invention are of the following formula ( ): wherein, R is hydrogen, or a sugar moiety or analog thereof optionally substituted at its 3â or its 5â position with a phosphorus derivative attached to the sugar moiety by an oxygen and including groups Q Q and Q or with a reactive precursor thereof suitable for nucleotide bond formation; Q is hydroxy phosphate a diphosphate; Q of or S; Q is CH âRâ, SâRâ, OâRâ, or NâRâRâ; each of Râ and Râ is independently hydrogen or C alkyl; B is a nucleic acid base or analog thereof that is a component of an oligonucleotide; Y is a functional linking group; each of to and q is independently 0 to 8, inclusive; r is 0 or 1; and Aâ is a leaving group. This invention is also directed to novel 3,4-disubstituted and 3,4,-trisubstituted pyrazolo[3,4- ]-pyrimidines and to the use of these nucleic acid bases in the preparation of oligonucleotides. The invention includes nucleosides and mono- and oligonucleotides comprising at least one of these pyrazolopyrimidines, and to the use of the resulting novel oligonucleotides for diagnostic purposes.

US Patent:

58247963, Oct 20, 1998

Filed:

Nov 4, 1994

Appl. No.:

8/334490

Inventors:

Charles R. Petrie - Woodinville WA
Rich B. Meyer - Woodinville WA
John C. Tabone - Bothell WA
Gerald D. Hurst - Iowa City IA

Assignee:

EPOCH Pharmaceuticals, Inc. - Bothell WA

International Classification:

C07H 1904
C07H 2100
C07H 2102
C07H 2104

US Classification:

536 267

Abstract:

This invention is directed to novel substituted nucleotide bases with a crosslinking arm which accomplish crosslinking between specific sites on adjoining strands of oligonucleotides or oligodeoxynucleotides. The invention is also directed to oligonucleotides comprising at least one of these crosslinking agents and to the use of the resulting novel oligonucleotides for diagnostic and therapeutic purposes. The crosslinking agents of the invention are of the following formula (I'): R. sub. 1 --B--(CH. sub. 2). sub. q --(Y). sub. r --(CH. sub. 2). sub. m --A'(I') wherein, R. sub. 1 is hydrogen, or a sugar moiety or analog thereof optionally substituted at its 3' or its 5' position with a phosphorus derivative attached to the sugar moiety by an oxygen and including groups Q. sub. 1 Q. sub. 2 and Q. sub. 3 or with a reactive precursor thereof suitable for nucleotide bond formation; Q. sub. 1 is hydroxy, phosphate or diphosphate; Q. sub. 2 is. dbd. O or. dbd.

US Patent:

58494820, Dec 15, 1998

Filed:

Jun 7, 1995

Appl. No.:

8/485611

Inventors:

Rich B. Meyer - Bothell WA
Howard B. Gamper - Woodinville WA
Igor V. Kutyavin - Bothell WA
Alexander A. Gall - Bothell WA
Charles R. Petrie - Woodinville WA
John C. Tabone - Bothell WA
Gerald D. Hurst - The Woodlands TX

Assignee:

Epoch Pharmaceuticals, Inc. - Bothell WA

International Classification:

C12Q 168
C07H 2104

US Classification:

435 6

Abstract:

Oligonucleotides (ODNs) include a sequence that is complementary to a target sequence in single stranded RNA, or single or double stranded DNA, and an alkylating function which after hybridization alkylates the target sequence. ODNs adapted for alkylating single stranded RNA, such as messenger RNA, are complementary to the target sequence in the Watson Crick sense. ODNs adapted for alkylating double stranded DNA have at least two alkylating functions and are complementary to the target sequence in the Hoogsteen or reverse Hoogsteen sense. With these ODNs both strands of the target sequence are alkylated. A third class of ODNs have at least approximately 26 nucleotide units in a continous sequence which are complementary to the target sequence of double stranded DNA, and the alkylating function is covalently attached to a nucleotide unit in the continuous sequence. Alkylation or cross-linking with this class of ODNs occurs in the presence of a recombinase enzyme.